ENDRA Life Sciences Receives Canadian Approval for Human Studies of its Taeus Device to Detect Non-Alcoholic Fatty Liver Disease

ENDRA Life Sciences Inc (NASDAQ: NDRA), announced on 10/16/18 that is has received approval from Health Canada for an Investigational Testing Authorization (ITA) to commence human studies with ENDRA's Thermo-Acoustic Enhanced Ultrasound (TAEUS™) clinical system targeting Non-Alcoholic Fatty Liver Disease (NAFLD). The ITA application was reviewed under a class II designation and the study will be conducted in collaboration with Imaging Laboratories at Robarts Research in London, Canada.